{"id":"combivir-kaletra","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Headache"},{"rate":"20-40","effect":"Lipid abnormalities (elevated cholesterol/triglycerides)"},{"rate":"5-10","effect":"Hepatotoxicity"},{"rate":"1-5","effect":"Pancreatitis"},{"rate":"5-15","effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Combivir (lamivudine/zidovudine) contains two nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, while Kaletra (lopinavir/ritonavir) is a protease inhibitor combination that blocks HIV protease. Together, they target two critical steps in the HIV replication cycle to reduce viral load and slow disease progression.","oneSentence":"This combination of two antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:11.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve or treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT02369406","phase":"PHASE2, PHASE3","title":"Early Infant HIV Treatment in Botswana","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2015-05-04","conditions":"HIV, Pediatric AIDS","enrollment":67},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT01061151","phase":"PHASE3","title":"Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-03-01","conditions":"HIV Infections","enrollment":3747},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00099632","phase":"PHASE2","title":"Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-03","conditions":"HIV Infections","enrollment":484},{"nctId":"NCT00270296","phase":"PHASE2","title":"Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":730},{"nctId":"NCT00086359","phase":"PHASE3","title":"Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections","enrollment":19},{"nctId":"NCT01818258","phase":"PHASE4","title":"IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2015-10-26","conditions":"HIV Positive, Malnourished","enrollment":52},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT00887120","phase":"PHASE2","title":"Dose Reduction of Lopinavir in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00621166","phase":"PHASE2","title":"Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-06","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT01125696","phase":"PHASE2","title":"Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-05","conditions":"HIV, Hepatitis B","enrollment":45},{"nctId":"NCT02150993","phase":"PHASE2, PHASE3","title":"First-Line Treatment for HIV-2","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01-26","conditions":"HIV-2 Infection","enrollment":210},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT00949234","phase":"PHASE2","title":"Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2010-03","conditions":"HIV Prevention, HIV Infections","enrollment":267},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT01088516","phase":"PHASE4","title":"Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa","status":"COMPLETED","sponsor":"University of Zambia","startDate":"2008-12","conditions":"HIV","enrollment":280},{"nctId":"NCT01583439","phase":"NA","title":"The Mochudi Prevention Project ART Protocol","status":"TERMINATED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2012-09","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00143689","phase":"PHASE4","title":"NRTI-Sparing Pilot Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2002-04","conditions":"HIV, Mitochondrial Toxicity","enrollment":13},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT01772940","phase":"PHASE4","title":"Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2008-12","conditions":"HIV-1 Infection","enrollment":425},{"nctId":"NCT00014937","phase":"NA","title":"Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT00424814","phase":"PHASE2, PHASE3","title":"Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2007-03","conditions":"HIV Infections","enrollment":105},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00034086","phase":"NA","title":"Study of Anti-HIV Therapy Intensification","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT00192621","phase":"PHASE4","title":"Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2004-11","conditions":"HIV Infections, Dyslipidemias, Glucose Metabolism Disorders","enrollment":50},{"nctId":"NCT00936195","phase":"PHASE3","title":"Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial","status":"WITHDRAWN","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-01","conditions":"HIV Infection, Pregnancy, Breastfeeding","enrollment":""},{"nctId":"NCT00405925","phase":"PHASE3","title":"FREE Study: Efficacy and Toxicity of Trizivir","status":"COMPLETED","sponsor":"Rijnstate Hospital","startDate":"2003-03","conditions":"HIV Infections","enrollment":207},{"nctId":"NCT00164736","phase":"PHASE3","title":"Breastfeeding, Antiretroviral, and Nutrition Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2004-03","conditions":"HIV Infections","enrollment":2369},{"nctId":"NCT00385645","phase":"PHASE4","title":"Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2006-05","conditions":"HIV Infections","enrollment":255},{"nctId":"NCT00966160","phase":"PHASE3","title":"CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes","status":"COMPLETED","sponsor":"University of Cologne","startDate":"1999-01","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":215},{"nctId":"NCT00234923","phase":"PHASE3","title":"Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-08","conditions":"HIV Infection","enrollment":138},{"nctId":"NCT00043953","phase":"PHASE2","title":"Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-08","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00075231","phase":"PHASE2","title":"A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-12","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT00162643","phase":"PHASE4","title":"PI Vs. NNRTI Based Therapy for HIV Advanced Disease","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2004-12","conditions":"Acquired Immunodeficiency Syndrome","enrollment":300},{"nctId":"NCT00122226","phase":"PHASE4","title":"MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2003-01","conditions":"HIV Infections, HIV-Associated Lipodystrophy Syndrome","enrollment":50},{"nctId":"NCT00139178","phase":"PHASE4","title":"Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.","status":"COMPLETED","sponsor":"Danish HIV Research Group","startDate":"2004-03","conditions":"HIV Associated Lipodystrophy Syndrome., HIV, Hypercholesterolemia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Combivir+Kaletra","genericName":"Combivir+Kaletra","companyName":"Hospital Clinic of Barcelona","companyId":"hospital-clinic-of-barcelona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of two antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication. Used for HIV-1 infection in treatment-naïve or treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}